KR100653485B1 - 항바이러스성 뉴클레오시드 유도체 - Google Patents

항바이러스성 뉴클레오시드 유도체 Download PDF

Info

Publication number
KR100653485B1
KR100653485B1 KR1020017008068A KR20017008068A KR100653485B1 KR 100653485 B1 KR100653485 B1 KR 100653485B1 KR 1020017008068 A KR1020017008068 A KR 1020017008068A KR 20017008068 A KR20017008068 A KR 20017008068A KR 100653485 B1 KR100653485 B1 KR 100653485B1
Authority
KR
South Korea
Prior art keywords
compound
amino
dioxolane
purin
hydroxymethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017008068A
Other languages
English (en)
Korean (ko)
Other versions
KR20020013485A (ko
Inventor
네 구엔-바
Original Assignee
샤이어 바이오켐 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 샤이어 바이오켐 인코포레이티드 filed Critical 샤이어 바이오켐 인코포레이티드
Publication of KR20020013485A publication Critical patent/KR20020013485A/ko
Application granted granted Critical
Publication of KR100653485B1 publication Critical patent/KR100653485B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020017008068A 1998-12-23 1999-12-22 항바이러스성 뉴클레오시드 유도체 Expired - Fee Related KR100653485B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11379798P 1998-12-23 1998-12-23
US60/113797 1998-12-23

Publications (2)

Publication Number Publication Date
KR20020013485A KR20020013485A (ko) 2002-02-20
KR100653485B1 true KR100653485B1 (ko) 2006-12-04

Family

ID=22351590

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017008068A Expired - Fee Related KR100653485B1 (ko) 1998-12-23 1999-12-22 항바이러스성 뉴클레오시드 유도체

Country Status (27)

Country Link
US (3) US6358963B1 (enExample)
EP (1) EP1140937B1 (enExample)
JP (1) JP2002533470A (enExample)
KR (1) KR100653485B1 (enExample)
CN (1) CN1117751C (enExample)
AP (1) AP2001002207A0 (enExample)
AT (1) ATE254126T1 (enExample)
AU (1) AU760875B2 (enExample)
BR (1) BR9916849A (enExample)
CA (1) CA2355712C (enExample)
CZ (1) CZ20012352A3 (enExample)
DE (1) DE69912842T2 (enExample)
DK (1) DK1140937T3 (enExample)
EA (1) EA004767B1 (enExample)
ES (1) ES2209532T3 (enExample)
HU (1) HUP0104827A3 (enExample)
ID (1) ID30477A (enExample)
IL (1) IL143867A0 (enExample)
MX (1) MXPA01006425A (enExample)
NO (1) NO20013163L (enExample)
NZ (1) NZ513094A (enExample)
OA (1) OA11741A (enExample)
PT (1) PT1140937E (enExample)
TR (1) TR200102501T2 (enExample)
UY (1) UY25878A1 (enExample)
WO (1) WO2000039143A2 (enExample)
ZA (1) ZA200105702B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004767B1 (ru) * 1998-12-23 2004-08-26 Шайре Байокем Инк. Аналоги нуклеозида (варианты) и их применение, комбинация и способ лечения вирусных инфекций, фармацевтическая композиция
AU3144801A (en) * 2000-02-11 2001-08-20 Shire Biochem Inc. Stereoselective synthesis of nucleoside analogues
WO2004009595A1 (en) * 2002-07-03 2004-01-29 Triangle Pharmaceuticals, Inc. Combination therapy with 1,3-dioxolanes and inosine monophosphate dehydrogenase inhibitors
IL166682A0 (en) 2002-08-06 2006-01-15 Pharmasset Ltd Processes for preparing 1,3-dioxolane nucleosides
US7706405B2 (en) * 2002-09-12 2010-04-27 Interdigital Technology Corporation System for efficient recovery of Node-B buffered data following MAC layer reset
WO2004048590A1 (en) * 2002-11-18 2004-06-10 Shire Biochem Inc. Stereoselective process for the production of dioxolane nucleoside analogues
DE10335061B4 (de) * 2003-07-31 2005-11-17 Wacker-Chemie Gmbh Verfahren zur Herstellung von OH-geschützten [4-(2,6-damino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol-Derivaten
KR101157468B1 (ko) * 2004-02-03 2012-07-06 에모리 유니버시티 1,3-디옥솔란 뉴클레오시드 제조방법
US7322412B2 (en) * 2004-08-30 2008-01-29 Halliburton Energy Services, Inc. Casing shoes and methods of reverse-circulation cementing of casing
EP2105412B1 (de) * 2008-03-20 2011-07-13 Befesa Salzschlacke Gmbh Hochtonerdehaltiger Rohstoff und Verfahren zur Herstellung
WO2012048455A1 (zh) * 2010-10-12 2012-04-19 武汉大学 一种抗病毒透皮吸收贴片及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
US4041037A (en) 1975-06-10 1977-08-09 American Home Products Corporation Antitumor derivatives of periodate-oxidized cytidine
JPS5668674A (en) 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
JPS5738774A (en) 1980-08-19 1982-03-03 Chugai Pharmaceut Co Ltd Uracil derivative and its preparation
US4479942A (en) 1981-08-10 1984-10-30 Fujisawa Pharmaceutical Co., Ltd. Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof
IL86007A0 (en) * 1987-04-09 1988-09-30 Wellcome Found 6-substituted purine nucleosides,their preparation and pharmaceutical compositions containing them
HU198933B (en) 1987-11-02 1989-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing new xanthine derivatives and pharmaceutical compositions comprising same as active ingredient
NZ228645A (en) 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5270315A (en) 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US4987224A (en) 1988-08-02 1991-01-22 University Of Georgia Research Foundation, Inc. Method of preparation of 2',3'-dideoxynucleosides
WO1994014802A1 (en) 1989-02-08 1994-07-07 Biochem Pharma Inc. Process for preparing substituted 1,3-oxathiolanes with antiviral properties
PT95516A (pt) * 1989-10-06 1991-08-14 Wellcome Found Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos
US5276151A (en) 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5700937A (en) 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
CA2095613C (en) 1990-11-13 2001-01-02 Bernard Belleau Substituted 1, 3-oxathiolanes and substituted 1, 3-dithiolanes with antiviral properties
WO1992010496A1 (en) 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
NZ241625A (en) 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9109506D0 (en) 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9200150D0 (en) 1992-01-06 1992-02-26 Wellcome Found Therapeutic nucleosides
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
GB9525606D0 (en) * 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration
US5792773A (en) 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
EA004767B1 (ru) * 1998-12-23 2004-08-26 Шайре Байокем Инк. Аналоги нуклеозида (варианты) и их применение, комбинация и способ лечения вирусных инфекций, фармацевтическая композиция

Also Published As

Publication number Publication date
EP1140937B1 (en) 2003-11-12
CZ20012352A3 (cs) 2001-10-17
CA2355712A1 (en) 2000-07-06
JP2002533470A (ja) 2002-10-08
TR200102501T2 (tr) 2002-01-21
CN1117751C (zh) 2003-08-13
EA200100711A1 (ru) 2001-12-24
CA2355712C (en) 2009-03-17
ES2209532T3 (es) 2004-06-16
AU1765700A (en) 2000-07-31
US20040058893A1 (en) 2004-03-25
AU760875B2 (en) 2003-05-22
CN1334814A (zh) 2002-02-06
DE69912842T2 (de) 2004-05-13
AP2001002207A0 (en) 2001-09-30
ATE254126T1 (de) 2003-11-15
ID30477A (id) 2001-12-13
US20010049372A1 (en) 2001-12-06
MXPA01006425A (es) 2002-06-04
DE69912842D1 (de) 2003-12-18
WO2000039143A2 (en) 2000-07-06
EA004767B1 (ru) 2004-08-26
UY25878A1 (es) 2001-08-27
US6545001B2 (en) 2003-04-08
US6358963B1 (en) 2002-03-19
BR9916849A (pt) 2001-10-30
OA11741A (en) 2005-05-13
NO20013163L (no) 2001-08-20
PT1140937E (pt) 2004-04-30
KR20020013485A (ko) 2002-02-20
HUP0104827A3 (en) 2002-08-28
EP1140937A2 (en) 2001-10-10
WO2000039143A3 (en) 2000-11-02
NZ513094A (en) 2004-05-28
HUP0104827A2 (en) 2002-06-29
DK1140937T3 (da) 2004-03-22
IL143867A0 (en) 2002-04-21
NO20013163D0 (no) 2001-06-22
ZA200105702B (en) 2002-10-11

Similar Documents

Publication Publication Date Title
JP4233111B2 (ja) 新規化合物と治療方法
CA1314875C (en) Therapeutic nucleosides
KR100242454B1 (ko) 1,3-옥사티올란누클레오시드유사체
KR100653485B1 (ko) 항바이러스성 뉴클레오시드 유도체
EP0515144A1 (en) 1,3-Oxathiolanes useful in the treatment of hepatitis
KR100331714B1 (ko) 디데옥시뉴클레오티드유사체를이용한바이러스감염의치료방법
EP0285432B1 (en) Therapeutic nucleosides
CN101132795B (zh) 用于hiv治疗的化合物
EP0669341A1 (en) Therapeutic Nucleosides
WO2001049700A1 (en) Imidazopyrimidine nucleoside analogues with anti-hiv activity
US10167302B2 (en) Phosphonate nucleosides useful in the treatment of viral diseases
JPH07508531A (ja) 治療用ヌクレオシド
CN101213198B (zh) 作为HIV抑制剂的1-[2′,3′-二脱氧-3′C-(羟甲基)-β-D-赤型环戊二烯并呋喃糖基]胞嘧啶衍生物
Wang Asymmetric synthesis and anti-HIV and anti-HBV activities of beta-L-2', 3'-dideoxy nucleosides, L-cyclopentyl and cyclopentenyl carbocyclic nucleosides
WO1993017035A1 (en) 2'ISODIDEOXY-β-D-NUCLEOSIDES AS STABLE ANTIVIRAL AGENTS
HK1122798B (en) 1- [2' , 3' -dideoxy-3' c- (hydroxymethyl) - beta-d-erythro-pentofuranosyl] cytosine derivatives as hiv inhibitors
HK1038189B (en) A method for preparation of a pharmaceutical composition comprising 1, 3-oxathiolane nucleoside analogues

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R19-X000 Request for party data change rejected

St.27 status event code: A-3-3-R10-R19-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20091120

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20101128

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20101128

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000